SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total

SCYNEXIS INC

Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.
Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.
Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.
SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.
SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update.

item 1.01 item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SCYNEXIS INC entered into Asset Purchase Agreement with Poxel SA valued at $8,000,000 (effective 2026-03-30).

Action: entry
Agreement: asset purchase
Counterparty: Poxel SA
Value: $8,000,000
Effective: 2026-03-30

Exact text from the filing

On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”)

View on SEC.gov

Browse all material agreements →

SCYNEXIS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-133250

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.